Monoclonal gammopathy of undetermined significance [21]

New England Journal of Medicine

Volumn 356, Issue 21, 2007, Pages 2223-2224

  Minisola, Salvatore ^a   Pepe, Jessica ^a   Romagnoli, Elisabetta ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

BONE MASS; CLINICAL PRACTICE; DRUG EFFICACY; LETTER; MONOCLONAL IMMUNOGLOBULINEMIA; OSTEOLYSIS; PRIORITY JOURNAL; VERTEBRA FRACTURE; BONE REMODELING; HUMAN; NOTE; PATHOPHYSIOLOGY; SPINE FRACTURE;

BONE REMODELING; DIPHOSPHONATES; HUMANS; MONOCLONAL GAMMOPATHIES, BENIGN; SPINAL FRACTURES;

EID: 34249733609     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc070145     Document Type: Letter

References (5)

1. Bladé J. Monoclonal gammopathy of undetermined significance. N Engl J Med 2006;355:2765-70.
2. Pepe J, Petrucci MT, Nofroni I, et al. Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance. Br J Haematol 2006;134:485-90.
3. Melton LJ III, Rajkumar SV, Khosla S, Achenbach SJ, Oberg AL, Kyle RA. Fracture risk in monoclonal gammopathy of undetermined significance. J Bone Miner Res 2004;19:25-30.
4. Politou M, Terpos E, Anagnostopoulos A, et al. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 2004;126:686-9.
5. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354:821-31.